References
- Tada H., Ishikawa M., Sato E., Suzuki T., Unno K., Miura K., Ohmiya Y., Nakai K. J. Clin. Pharm. Ther. 1989; 14: 145
- Karim A., Bums T., Wearmer L., Streicher J., Palmer M. Clin. Pharmacol. Therapeutics 1985; 38: 77
- Spector S. L., Rohr A. S., Rachelefsky G. S., Kartz R. M., Siegel S. C., Wo J., Gracey V. J. Allergy Clin. Immunol. 1985; 75: 105
- Hendeles L., Weinberger M., Allergy J. Clin. Immunol. 1986; 78: 743
- Milavetz G., Vaughan L., Weinberger M., Harris J., Mullenix T., Allergy J. Clin. Immunol. 1986; 77: 146
- Peh K. K., Yuen K. H. Drug Dev. Ind. Pharm. 1996; 22(4)351
- Peh K. K., Yuen K. H. Drug Dev. Ind. Pharm. 1996; 22(11)1133
- Peh K. K., Yuen K. H. Drug Dev. Ind. Pharm. 1995; 21(13)1545
- Skelly J. P. Division Guidelines for the Evaluation of Controlled Release Products. Division of Biopharmaceutics. 1984, Food and Drug Administration
- Wagner J. G. Fundamentals of Clinical Pharmacokinetics, 1st ed. Drug Intelligence, Hamilton, IL 1975; 285
- Yuen K. H., Deshmukh A. A., Newton J. M., Short M., Melchor R. Int. J. Pharm. 1993; 97: 61
- Westlake W. J. Biophamceutical Statistics for Drug Development, K. E. Peace. Marcel Dekker, New York 1988; 329
- Kappas A., Alvares A. P., Anderson K. E., Pantuck E. J., Pantuck C. B., et al. Clin. Pharmacol. Ther. 1978; 23: 445
- Anderson K. E., Kappas A. Sustained Release Theophylline in the Treatment of Chronic Reversible Airways Obstruction, Jonkman, et al. Excerpta Medica, Amsterdam 1984; 83